Inherited genetic variation in childhood acute lymphoblastic leukemia

Moriyama, Takaya; Relling, Mary V.; Yang, Jun J.

doi:10.1182/blood-2014-12-580001

Cited by 127 publications

(102 citation statements)

References 108 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recent genome-wide association studies have shown certain single nucleotide polymorphisms in genes like ARID5B, IKZF1, CEBPE, CDKN2A, PIP4K2A, and GATA3 to be associated with an increased risk for developing ALL. 8 However, these findings do not account for the vast majority of cases.…”

Section: Acute Lymphoblastic Leukemiamentioning

confidence: 92%

Progress and Prospects in Pediatric Leukemia

Madhusoodhan

Carroll

Bhatla

2016

Current Problems in Pediatric and Adolescent Health Care

View full text Add to dashboard Cite

Section: Acute Lymphoblastic Leukemiamentioning

confidence: 92%

Progress and Prospects in Pediatric Leukemia

Madhusoodhan

Carroll

Bhatla

2016

Current Problems in Pediatric and Adolescent Health Care

View full text Add to dashboard Cite

“…The genetic landscape produced by inherited germline variations contributes to leukemogenesis and disease outcome, 31 and is a biological component that contributes to racial, ethnic and other health disparities in ALL. 32 This is particularly relevant in CRLF2 B-ALL which occurs five times more often in Hispanic children than others 28 and comprises more than half of the ALL cases in children with Down Syndrome.…”

mentioning

confidence: 99%

A novel xenograft model to study the role of TSLP-induced CRLF2 signals in normal and malignant human B lymphopoiesis

et al. 2015

View full text Add to dashboard Cite

T hymic stromal lymphopoietin (TSLP) stimulates in vitro proliferation of human fetal B-cell precursors. However, its in vivo role during normal human B lymphopoiesis is unknown. Genetic alterations that cause overexpression of its receptor component, cytokine receptor-like factor 2 (CRLF2), lead to high-risk B-cell acute lymphoblastic leukemia implicating this signaling pathway in leukemogenesis. We show that mouse thymic stromal lymphopoietin does not stimulate the downstream pathways (JAK/STAT5 and PI3K/AKT/mTOR) activated by the human cytokine in primary high-risk leukemia with overexpression of the receptor component. Thus, the utility of classic patient-derived xenografts for in vivo studies of this pathway is limited. We engineered xenograft mice to produce human thymic stromal lymphopoietin (+T mice) by injection with stromal cells transduced to express the cytokine. Control (-T) mice were produced using stroma transduced with control vector. Normal levels of human thymic stromal lymphopoietin were achieved in sera of +T mice, but were undetectable in -T mice. Patient-derived xenografts generated from +T as compared to -T mice showed a 3-6-fold increase in normal human B-cell precursors that was maintained through later stages of B-cell development. Gene expression profiles in high-risk B-cell acute lymphoblastic leukemia expanded in +T mice indicate increased mTOR pathway activation and are more similar to the original patient sample than those from -T mice. +T/-T xenografts provide a novel pre-clinical model for understanding this pathway in B lymphopoiesis and identifying treatments for high-risk B-cell acute lymphoblastic leukemia with overexpression of cytokine-like factor receptor 2.

show abstract

“…High-risk Ph-like ALL is especially important since it is characterized by tyrosine kinase activation that can be inhibited with currently available pharmacological agents [4,5]. Genomic profiling has also aided identification of inherited risk factors for leukaemia development including GATA3, IKZF1, CEBPE and CKDN2A [6].…”

Section: Dear Readersmentioning

confidence: 99%